Cryptotanshinone chemosensitivity potentiation by TW-37 in human oral cancer cell lines by targeting STAT3–Mcl-1 signaling

In-Hyoung Yang1,2†, Seung-Hyun Hong3†, Minjung Jung3, Chi-Hyun Ahn3, Hye-Jung Yoon3, Seong Doo Hong3, Sung-Dae Cho3* and Ji-Ae Shin3* 

Abstract

Background: Despite being one of the leading cancer types in the world, the diagnosis of oral cancer and its suitable therapeutic options remain limited. This study aims to investigate the single and chemosensitizing effects of TW-37, a BH3 mimetic, in oral cancer cell lines.

Methods: We assessed the single and chemosensitizing effects of TW-37 in vitro using trypan blue exclusion assay, Western blotting, DAPI staining, Annexin V–FITC/PI double staining, and quantitative real-time PCR. Mcl-1 overexpression models were established by transforming vector and transient transfection was performed to test for apoptosis.

Results: TW-37 enhanced the cytotoxicity of human oral cancer cell lines by inducing caspase-dependent apoptosis, which correlates with the reduction of the myeloid cell leukemia-1 (Mcl-1) expression via transcriptional and post-translational regulation. The ectopic expression of Mcl-1 partially attenuated the apoptosis-inducing capacity of TW-37 in human oral cancer cell lines. Besides, TW-37 decreased the phosphorylation of signal transducer and activator of transcription 3 (STAT3) at Tyr705 and nuclear translocation in human oral cancer cell lines at the early time points. Furthermore, TW-37 potentiated chemosusceptibility of cryptotanshinone in human oral cancer cell lines by suppressing STAT3–Mcl-1 signaling compared with either TW-37 or cryptotanshinone alone, resulting in potent apoptosis.

Conclusions: This study not only unravels the single and chemosensitizing effects of TW-37 for treatment of human oral cancer but also highlights the likelihood of TW-37 as a good therapeutic strategy to enhance the prognosis of patients with oral cancer in the future.

Keywords: TW-37, Cryptotanshinone, Chemosensitivity, STAT3, Mcl-1, Oral cancer, Apoptosis

Background

Globally, head and neck squamous cell carcinoma (HNSCC) is one of the leading cancer types, of which oral squamous cell carcinoma constitutes > 90% of cases [1]. Despite witnessing a decline in the incidence of some cancer types, the incidence and mortality of oral cancer have steadily increased in both males and females [2]. The standard therapeutic options for managing patients with oral cancer include surgery, radiotherapy, and chemotherapy, which depend on the type, location, and stage of cancer at diagnosis. Despite significant advancements in the approaches of oral cancer treatment over the past decades, effective diagnosis and suitable therapeutic options of oral cancer remain limited, thereby triggering low prognosis of patients [3]. Hence, finding...
suitable therapeutic options for the treatment of patients with oral cancer is of utmost significance to enhance the therapeutic outcome.

In cancer therapy, targeting anti-apoptotic Bcl-2 family proteins is an attractive approach because of their oncogenic potential. The “BH3 mimetics” were designed to mimic the BH3 domain of pro-apoptotic Bcl-2 proteins and to antagonize anti-apoptotic Bcl-2 family proteins, resulting in apoptosis [4]. Of these, TW-37 is an analog of gossypol, a plant-derived polyphenolic aldehyde, which can bind to Bcl-2, Bcl-xL, and myeloid cell leukemia-1 (Mcl-1) in the nanomolar range [5, 6]. A growing number of studies have demonstrated the therapeutic potential of TW-37 against various types of cancer by inducing S-phase cell cycle arrest or apoptosis in vitro and in vivo [7–9]. In HNSCC, TW-37 has also been reported to suppress tumor angiogenesis and sensitize the antitumor effect of cisplatin [10]. Recently, our team demonstrated that TW-37 functions as a potential apoptosis-inducing agent for the treatment of oral cancer by reducing heme oxygenase-1 and Bcl-2 [11, 12]. Furthermore, in combination with conventional chemotherapeutic drugs like cisplatin and 5-fluorouracil, TW-37 was sufficient in potentiating the chemosensitivity of tumors by inducing apoptosis [13, 14]. Hence, therapeutic approaches by TW-37 alone or combined with chemotherapeutic drugs are crucial to augment the survival of patients with oral cancer.

Based on the related literature [15], this study hypothesizes that the transcriptional regulation of Mcl-1 in human oral cancer cell lines upon TW-37 treatment could correlate with the signal transducer and activator of transcription (STAT) family members, including STAT3 (H1). In addition, we hypothesize that the combination of TW-37 and cryptotanshinone at low concentration ranges could potently suppress the Mcl-1 expression by inhibiting the STAT3 activation (H2). Hence, this study aims to explore whether TW-37 could be a valuable therapeutic option as monotherapy in human oral cancer, as well as combination therapy with cryptotanshinone, by targeting STAT3–Mcl-1 signaling.

**Methods**

**Cell culture and chemical preparation**

HSC-3, Ca9.22, and HSC-4 cell lines are obtained from Hokkaido University (Hokkaido, Japan), and the HN22 cell line was provided by Dankook University (Cheonan, Republic of Korea). All cell lines were maintained in DMEM/F12 medium (WELGENE, Gyeongsan, Republic of Korea) supplemented with 10% fetal bovine serum and 1% antibiotics (penicillin/streptomycin) at 37 °C in a 5% CO2 incubator. In addition, TW-37 was purchased from ApexBio (Houston, TX, USA), whereas cryptotanshinone and cycloheximide (CHX) were purchased from Sigma-Aldrich (St Louis, MO, USA). ABT-737 and Stattic were supplied from Selleckchem (Houston, TX, USA), Z-VAD-FMK was purchased from R&D Systems (Minneapolis, MN, USA), and MG132 was provided from Santa Cruz Biotechnology (Santa Cruz, CA, USA). All chemicals were dissolved in dimethyl sulfoxide and stored at −20 °C.

**Trypan blue exclusion assay**

We seeded all cell lines in six-well plates and treated those with TW-37. Figure 1a shows the structure of TW-37. Then, 48 h after the TW-37 treatment, all cell lines were stained with 0.4% trypan blue solution (Gibco, Paisley, UK), and viable cell lines were counted using a hemocytometer.

**Western blotting**

All cell lines were extracted with 1X RIPA lysis buffer (EMD Millipore, Billerica, CA, USA) using phosphatase inhibitor tablets (Thermo Scientific Inc., Rockford, IL, USA) and protease inhibitor cocktails (Roche, Mannheim, Germany). We then performed protein quantification using a DC protein assay kit (Bio-Rad Laboratories, Madison, WI, USA) and protease inhibitor tablets (Thermo Scientific Inc., Rockford, IL, USA) using phosphatase inhibitors. All cell lines were extracted with 1X RIPA lysis buffer (EMD Millipore, Billerica, CA, USA) and protease inhibitor cocktails (Roche, Mannheim, Germany). We then performed protein quantification using a DC protein assay kit (Bio-Rad Laboratories, Madison, WI, USA) and protease inhibitor tablets (Thermo Scientific Inc., Rockford, IL, USA) using phosphatase inhibitors.

**DAPI staining**

After the TW-37 treatment, all cell lines were fixed overnight with 100% ethanol at −20 °C and 100% methanol at RT for 10 min. The fixed cell lines were then deposited on slides and stained with DAPI solution (5 μg/mL). Furthermore, we observed morphological changes of nuclei in apoptotic cell lines using a fluorescence microscope (Leica DMi8; Leica Microsystems GmbH, Wetzlar, Germany).

**Annexin V–FITC/PI double staining**

We measured the induction of apoptosis using the FITC Annexin V Apoptosis Detection Kit (BD Pharmingen,
San Jose, CA, USA) according to the manufacturer's protocol. Briefly, all floating and adherent cell lines were collected, washed two times with PBS, and pelleted by centrifugation. After that, cell lines were resuspended in annexin V binding buffer containing 3-μL annexin V–FITC and 1-μL PI and incubated for 15 min at RT in the dark. Subsequently, we transferred cell lines to a FACS tube and analyzed by flow cytometry using a FACSCalibur and counted 10,000 events per sample.

**Quantitative real-time PCR**

Using TRIzol Reagent (Life Technologies, Carlsbad, CA, USA), the total RNA was extracted. Afterward, 1 μg of RNA was reverse transcribed using an AMPIGENE cDNA Synthesis Kit (Enzo Life Sciences, Inc., NY, USA), and the resultant cDNA was subjected to PCR using AMPIGENE qPCR Green Mix Hi-Rox (Enzo Life Sciences). We performed real-time PCR using the StepOnePlus Real-Time PCR System (Applied Biosystems, CA,
USA). In this study, the PCR conditions for all genes were as follows: 95 °C for 2 min, followed by 40 cycles of 95 °C for 10 s and 60 °C for 30 s. The relative amount of Mcl-1 gene was normalized to the amount of GAPDH and was evaluated using the 2^−ΔΔCt method. The qPCR primers were as follows: Mcl-1 sense, 5′-GTA TCA CAG TTC TCT GAA TTC TCG TAA GG-3′; Mcl-1 antisense, 5′-CCA CCT TCT AGG TCC TCT ACA T-3′; GAPDH sense, 5′-GTG GTC TCC TCT GAC TTC AAC-3′; and GAPDH antisense, 5′-CCT GTT GCT GTA GCC AAA TTC-3′.

Plasmid construction and transient transfection
We amplified the open reading frame of human Mcl-1 (NM_021960) gene from cDNA that was synthesized in HSC-3 cell lines using gene-specific primers (primer sequence: Mcl-1 sense, 5′-GAA TTC ATG TTT GGC CTC AAA AGA-3′, with an included EcoRI site; Mcl-1 antisense, 5′-GAA TTC CTA TCT TAT TAG ATA TGC-3′, with an included EcoRI site), followed by cloning into a pGEM® T-easy vector (Promega, Madison, WI, USA). The Mcl-1 was then established by sequence analysis. Finally, we cloned the Mcl-1 gene into the multi-cloning site of the pcDNA3.1 (+) vector (Invitrogen, San Diego, CA, USA). For the overexpression vector transfection, we transfected cell lines with vector constructs (pcDNA3.1 or pcDNA3.1-Mcl-1) using Lipofectamine 3000 transfection reagent (Life Technologies) according to the manufacturer’s protocol.

Statistical analysis
We compared the control and the treated groups through Student’s t-test (two tailed) using SPSS 22 (SPSS, Chicago, IL, USA). In this study, P<0.05 was considered statistically significant.

Results
TW-37 represses cell viability and induces apoptosis in human oral cancer cell lines
We first performed a concentration–response test using the trypan blue exclusion assay to assess the potential cytotoxic effect of TW-37 on human oral cancer cell lines. TW-37 exhibited a concentration-dependent cytotoxic effect on HSC-3 cell lines (Fig. 1b). In addition, similar cytotoxicity was observed in the three human oral cancer cell lines, including Ca9.22, HSC-4, and HN22 (Additional file 1: Figure S1a). Furthermore, we analyzed the levels of cleaved caspase-3 and cleaved PARP using Western blotting to determine whether the cytotoxic effect of TW-37 was because of the induction of apoptosis. TW-37 induced apoptosis in four human oral cancer cell lines (Fig. 1c; Additional file 1: Figure S1b). Likewise, morphological changes in nuclei by fluorescence-based analysis exhibited TW-37-induced apoptosis in four human oral cancer cell lines, as evidenced by chromatin condensation or DNA fragmentation (Fig. 1d; Additional file 1: Figure S1c). Next, we examined the apoptotic effect of TW-37 using flow cytometric analysis. The rate of annexin V-positive cell lines was increased from 11.29% in the vehicle control group to 22.78 or 42.15% in the TW-37 treatment group (Fig. 1e). Moreover, TW-37-induced apoptosis relied on caspase activation in human oral cancer cell lines (Additional file 1: Figure S2). The findings provided above demonstrated that TW-37 elicits

Table 1 List of antibodies and dilutions used in Western blot

| Antibody               | Manufacturer                  | Catalog number | Dilution |
|------------------------|-------------------------------|----------------|----------|
| Cleaved PARP           | Cell Signaling Technology     | 9541           | 1:3000   |
| Cleaved caspase 3      | Cell Signaling Technology     | 9664           | 1:3000   |
| Actin                  | Santa Cruz Biotechnology      | sc-47778       | 1:5000   |
| Mcl-1                  | Cell Signaling Technology     | 5453           | 1:3000   |
| Bcl-2                  | Santa Cruz Biotechnology      | sc-7382        | 1:3000   |
| Bcl-xl                 | Cell Signaling Technology     | 2764           | 1:3000   |
| p-STAT3(Y705)          | Cell Signaling Technology     | 9145           | 1:3000   |
| p-STAT3(S727)          | Cell Signaling Technology     | 9134           | 1:3000   |
| STAT3                  | Cell Signaling Technology     | 4904           | 1:3000   |
| p-STAT5(Y694)          | Cell Signaling Technology     | 4322           | 1:3000   |
| STAT5                  | Cell Signaling Technology     | 4904           | 1:3000   |
| α-Tubulin              | Santa Cruz Biotechnology      | sc-5286        | 1:3000   |
| Lamin B                | Santa Cruz Biotechnology      | sc-6217        | 1:3000   |
| Goat IgG antibody(HRP) | GeneTex                       | GTX232040-01   | 1:5000   |
| Mouse IgG antibody(HRP)| GeneTex                       | GTX213111-01   | 1:2000   |
| Rabbit IgG antibody(HRP)| GeneTex                  | GTX213110-01   | 1:5000   |
cytotoxicity in human oral cancer cell lines because of apoptosis induced by the caspase-dependent mechanism.

**TW-37 augments apoptosis in human oral cancer cell lines by inhibiting the Mcl-1 expression**

As TW-37 is a potent inhibitor of anti-apoptotic Bcl-2 family proteins, such as Bcl-2, Bcl-xL, and Mcl-1, we assessed whether TW-37-induced apoptosis in human oral cancer cell lines could regulate these proteins. The findings revealed that the Mcl-1 expression notably decreased after the TW-37 treatment, whereas the Bcl-2 and Bcl-xL expressions were inconsistent (Fig. 2a). We observed a decline in the Mcl-1 expression after 12 h TW-37 treatment, and PARP cleavage was coordinately enhanced at similar time points (Fig. 2b). In addition, we performed real-time PCR in a time-dependent manner to determine whether TW-37 could affect the levels of Mcl-1 mRNA. TW-37 markedly decreased the Mcl-1 mRNA levels up to 6 h, alleviated after 12 h, and then weakly decreased after 24 or 48 h (Fig. 2c and Additional file 1: Figure S3). Thus, we next investigated whether TW-37 treatment for 24 or 48 h could regulate the protein stability of Mcl-1 in human oral cancer cell lines. After treatment with CHX to stop new protein synthesis, TW-37 strongly degraded Mcl-1 protein (Fig. 2d). Consistently, the degradation of Mcl-1 protein in cells treated

![Image](image-url)
with TW-37 for 24 and 48 h was restored by MG132, a proteasome inhibitor (Fig. 2e). These findings suggested that the suppression of the Mcl-1 expression in a transcriptional and post-translational manner could contribute to TW-37-induced apoptosis in human oral cancer cell lines.

**Ectopic expression of Mcl-1 abolishes TW-37-induced apoptosis in human oral cancer cell lines**

In this study, cell lines were transiently transfected with pcDNA3.1 (a control vector) and pcDNA3.1-Mcl-1 (to overexpress Mcl-1) to elucidate the biological role of Mcl-1 protein in TW-37-induced apoptosis. The ectopic expression of Mcl-1 modestly attenuated the expression of cleaved PARP after the TW-37 treatment (Fig. 3a). We further established the suppressive effect of Mcl-1 in TW-37-induced apoptosis using flow cytometric analysis. The rate of annexin V-positive cell lines after the TW-37 treatment (52.15%) was partially diminished by the ectopic expression of Mcl-1 (43.02%; Fig. 3b). These findings indicated that the Mcl-1 suppression could be partly needed for TW-37-induced apoptosis in human oral cancer cell lines.

**TW-37 decreases the STAT3 phosphorylation at Tyr<sup>705</sup> and nuclear translocation in human oral cancer cell lines**

STAT signaling pathway plays a vital role in oncogenesis through the modulation of genes involved in anti-apoptotic Bcl-2 proteins such as Mcl-1 [16]. In this study, we explored the phosphorylation of STAT3 and STAT5 at early time points after the TW-37 treatment to determine whether TW-37 could regulate STAT family proteins. TW-37 markedly suppressed the STAT3 phosphorylation at Tyr<sup>705</sup> in a time-dependent manner but not the STAT3 phosphorylation at Ser<sup>727</sup> and STAT5 phosphorylation at Tyr<sup>694</sup> (Fig. 4a, b). Consistently, we observed a reduction of the STAT3 phosphorylation at Tyr<sup>705</sup> in a concentration-dependent manner in other human oral cancer cell lines, including Ca9.22, HSC-4, and HN22 (Additional file 1: Figure S1d). As the STAT3 phosphorylation

---

**Fig. 3** Ectopic expression of Mcl-1 attenuates TW-37-induced apoptosis. HSC-3 cell lines were treated with DMSO or 5-μM TW-37 for 48 h after transiently transfected with 0.5-μg pcDNA3.1 or pcDNA3.1-Mcl-1 for 6 h. **a** Protein levels of myeloid cell leukemia-1 (Mcl-1) and cleaved PARP were determined using Western blotting. Actin was used as a loading control. **b** FACS analysis of annexin V/PI staining. All bar graphs represent mean ± SD of three independent experiments. *P < 0.05; **P < 0.005
exhibits translocation into the nucleus, we examined the phosphorylation status of STAT3 in the nucleus after the TW-37 treatment. Notably, TW-37 inhibited the nuclear translocation of p-STAT3Tyr705 (Fig. 4c). These results suggested that TW-37 triggers the suppression of p-STAT3Tyr705 and nuclear translocation in human oral cancer cell lines.

TW-37 enhances the chemosensitivity of cryptotanshinone by modulating the STAT3–Mcl-1 axis in human oral cancer cell lines

We optimized the concentrations of TW-37 and cryptotanshinone to exclude their direct cytotoxic efficiency on human oral cancer cell lines to investigate the synergistic effect of TW-37 with cryptotanshinone as a potent STAT3 inhibitor. The combined treatment of TW-37 and cryptotanshinone potently decreased the growth of HSC-3 cell lines compared with either TW-37 or cryptotanshinone alone (Fig. 5a). Moreover, the rate of annexin V-positive cell lines was enhanced after the combined treatment of TW-37 and cryptotanshinone (Fig. 5b). Furthermore, we confirmed the levels of p-STAT3 Tyr705 and Mcl-1 by Western blotting to elucidate whether the synergistic effect of TW-37 with cryptotanshinone correlated with STAT3–Mcl-1 signaling. The combined treatment of TW-37 and cryptotanshinone remarkably abolished the expression of p-STAT3 Tyr705 and Mcl-1 compared with either TW-37 or cryptotanshinone alone, resulting in a potent induction of apoptosis (Fig. 5c). These findings suggested that TW-37 can synergistically induce the chemosensitivity of cryptotanshinone by inducing apoptosis through suppressing STAT3–Mcl-1 signaling in human oral cancer cell lines.

Discussion

Although targeting anti-apoptotic Bcl-2 family proteins is a promising and well-established therapeutic strategy for the treatment of various tumors, developing Bcl-2 inhibitors and exploring their efficiency because of the oncogenic potential of anti-apoptotic Bcl-2 family proteins are still worthwhile. This study reports the single and chemosensitizing effects of TW-37, a potent inhibitor of anti-apoptotic Bcl-2 family proteins, for the treatment of oral cancer. Our analysis of the effect of TW-37 on anti-apoptotic Bcl-2 family proteins in human oral cancer cell lines revealed that TW-37 suppressed the Mcl-1 expression at the transcriptional and post-translational levels, resulting in apoptosis (Fig. 2). Mcl-1, an anti-apoptotic member of Bcl-2 family proteins, is regulated at the transcriptional, post-transcriptional, and post-translational levels upon several factors such as growth factors [17]. In addition, Mcl-1 is overexpressed in various types of cancer, which is
related to the evasion of cell death and acquisition of resistance to chemotherapeutic drugs [18]. Specifically, we previously established that the Mcl-1 expression was higher in human oral tumors compared with healthy oral mucosa and was accountable for neoplastic cell transformation under 12-O-tetradecanoylphorbol-13-acetate or epidermal growth factor [19]. This study reported that the ectopic expression of Mcl-1 partly declined the apoptotic activity of TW-37 in human oral cancer cell lines, suggesting that regulation of the Mcl-1 expression is needed for TW-37-induced apoptosis in human oral cancer cell lines (Fig. 3). Hence, seeking a Mcl-1-targeting inhibitor could provide a potential therapeutic benefit for oral cancer therapy.

STAT3, one of the STAT family members, is a transcription factor playing a vital role in pathological processes of cancer. Notably, the constitutive phosphorylation of STAT3 correlates with tumor initiation and progression by suppressing apoptosis and inducing proliferation, invasion, metastasis, and angiogenesis, which is accompanied by dimerization, translocation to the nucleus, and binding to promoters of target genes [20, 21]. We previously illustrated that the phosphorylated STAT3 levels markedly elevated in tissues obtained from patients with oral cancer compared with tissues obtained from the healthy oral mucosa, suggesting that p-STAT3 is a good prognostic indicator of oral cancer [22]. In addition, Zhou et al. demonstrated that the deletion
The results showed that these STAT3 inhibitors significantly decreased the cell viability and induced apoptosis in human oral cancer cell lines via the downregulation of Mcl-1 (Additional file 1: Figure S4a-c). In contrast, the ectopic expression of Mcl-1 had no effect on the activation of STAT3 (Additional file 1: Figure S4d). Moreover, we compared the effects of TW-37 with those of ABT-737 on p-STAT3-Mcl-1 signaling: TW-37 significantly inhibited p-STAT3-Mcl-1 signaling; however, ABT-737 did not affect it although both inhibitors showed similar apoptotic efficiency (Additional file 1: Figure S5). Thus, our findings indicate that the decreased expression of Mcl-1 protein induced by TW-37 in human oral cancer cell lines could arise from the inhibition of STAT3 activation and nuclear translocation, thereby validating H1 of this study. Nevertheless, further studies are required to demonstrate the role of STAT3 on reduced Mcl-1 promoter activity upon TW-37 treatment.

To date, numerous STAT3-targeted therapies inhibiting the SH2 domain, upstream tyrosine kinase, and DNA-binding domain have been considered potential therapeutic approaches for clinical applications because targeting STAT3 could be a reasonable strategy for the development of chemotherapeutic drugs against cancer [23]. Cryptotanshinone, one of the major active ingredients isolated from the traditional Chinese medicinal herb Salvia miltiorrhiza Bunge (red sage), is a STAT3 inhibitor that binds to the SH2 domain of STAT3 [24]. In addition, cryptotanshinone reportedly suppressed the cell proliferation and induced cell cycle arrest and apoptosis in various cancer types by suppressing JAK2–STAT3 signaling, as well as PI3K-Akt-NF-kB signaling [25–27]. Reportedly, cryptotanshinone enhances the chemosensitivity of conventional chemotherapeutic drugs, such as doxorubicin and paclitaxel, in cancer cell lines by inhibiting the STAT3 signaling pathway [28, 29]. Accordingly, we optimized the concentrations of TW-37 and cryptotanshinone to exclude their direct cytotoxic efficiency on human oral cancer cell lines. Our findings revealed that the combination of TW-37 and cryptotanshinone further enhanced the chemosensitivity of human oral cancer cell lines than a single drug alone, which was, perhaps, caused by the inhibition of STAT3–Mcl-1 signaling (Fig. 5), thereby validating H2 of this study. Hence, this study suggests that TW-37 potentiates the apoptotic effect of cryptotanshinone in human oral cancer cell lines by suppressing STAT3–Mcl-1 signaling.

Conclusion
This study demonstrates that TW-37 alone and in combination with cryptotanshinone exerts a potent apoptotic effect on human oral cancer cell lines by inhibiting STAT3–Mcl-1 signaling. Overall, this study highlights that targeting STAT3 using TW-37 could be an attractive approach in enhancing the prognosis of patients with oral cancer in the future.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12935-020-01495-2.

Acknowledgements
We would like to thank Enago (www.enago.co.kr) for English language editing. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2019R1A2C1085896 and 2020R1C1C1005480).
Authors' contributions

IHY and SHH conducted most of the experiments and drafted the manuscript. MJ and CHA interpreted the data, and HIY and SDH performed statistical analysis. SDC and JAS supervised and wrote the final draft of the paper. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Cancer Center, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. 2 Department of Pediatrics, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. 3 Department of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul 03080, Republic of Korea.

Received: 27 May 2020 Accepted: 12 August 2020 Published online: 26 August 2020

References

1. Ali J, Sabitha B, Jan HU, Haider SA, Khan AA. Ali SS Genetic etiology of oral cancer. Oral Oncol. 2017;70:23–8.
2. Conlon KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2018;124:2785–800.
3. Rivera C. Essentials of oral cancer. Int J Clin Exp Pathol. 2015;8:11884–94.
4. Billard C. BH3 mimetics: status of the field and new developments. Mol Cancer Ther. 2013;12:1691–700.
5. Labi V, Grespi F, Baumgartner F, Villunger A Targeting the Bcl‑2‑regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Cell Death Differ. 2008;15:977–87.
6. Vogler M. Targeting BCL2-Proteins for the Treatment of Solid Tumours. Adv Med. 2014;2014:943648.
7. Wang Z, Azmi AS, Ahmad A, Banerjee S, Wang S, Sarkar FH, et al. TW‑37, a small-molecule inhibitor of Bcl‑2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch‑1 signaling pathway. Cancer Res. 2009;69:2757–65.
8. Lei S, Ding Y, Fu Y, Wu S, Xie X, Wang C, et al. The preclinical analysis of TW‑37 as a potential anti‑colorectal cancer cell agent. PLoS ONE. 2017;12:e0184501.
9. Klenke S, Akdeli N, Stelmach P, Heukamp L, Schulte JH, Bachmann HS. The small molecule Bcl‑2/Mcl‑1 inhibitor TW‑37 shows single‑agent cytotoxicity in neuroblastoma cell lines. BMC Cancer. 2019;19:243.
10. Ashimori N, Zeilin BD, Zhang Z, Warner K, Turkenicz IM, Spalding AC, et al. TW‑37, a small‑molecule inhibitor of Bcl‑2, mediates S‑phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Mol Cancer Ther. 2009;8:893–903.
11. Yang HJ, Ahn CH, Cho NP, Jin B, Lee W, Jung YC, et al. Herne Oxygenase‑1 is a key molecule underlying differential response of TW‑37‑induced apoptosis in human mucoepidermoid carcinoma cells. Molecules. 2019;24:1700.
12. Ahn CH, Lee W, Jung YC, Shin JA, Hong KO, Choi S, et al. Antitumor effect of TW‑37, a BHA mimetic in human oral cancer. Lab Anim Res. 2019;35:194–201.
13. Wang H, Zhang Z, Wei X. Dai R Small‑molecule inhibitor of Bcl‑2 (TW‑37) suppresses growth and enhances cisplatin‑induced apoptosis in ovarian cancer cells. J Ovarian Res. 2015;8:3.
14. Lu Y, Huang H, Yang H, Chen D, Wu S, Jiang Z, et al. Small molecule inhibitor TW‑37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma. Cell Cycle. 2017;16:1376–83.
15. Zhou M, Zhao J, Zhang Q, Jin X, Liao M, Zhang L, et al. Nicotine upregulates the level of Mcl‑1 through STAT3 in H1299 cells. J Cancer. 2020;11:1270–6.
16. Buettner R, Mora LB. Jove R Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002;8:945–54.
17. De Blasio A, Vento R, Di Fiore R Mcl‑1 targeting could be an intriguing perspective to cure cancer. J Cell Physiol. 2018;233:8482–98.
18. Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, et al. Targeting Mcl‑1 for the therapy of cancer. Expert Opin Investig Drugs. 2011;20:1397–411.
19. Shin JA, Jung JY, Ryu MH, Safe S, Cho SD. Mithramycin A inhibits myeloid cell leukemia‑1 to induce apoptosis in oral squamous cell carcinomas and tumor xenograft through activation of Bax and oligomerization. Mol Pharmacol. 2013;83:33–41.
20. Sixeven KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, et al. Targeting STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta. 2014;1845:136–54.
21. Lee H, Jeong AJ, Ye SK Highlighted STAT3 as a potential drug target for cancer therapy. BMB Rep. 2019;52:415–23.
22. Kim LH, Khadka S, Shin JA, Jung JY, Ryu MH, Yu HJ, et al. Nitidine chloride acts as an apoptosis inducer in human oral cancer cells and a nude mouse xenograft model via inhibition of STAT3. Oncotarget. 2017;8:91306–15.
23. Wong ALA, Hirpara JL, Pervaze S, Eu JQ, Sethi G, Goh BC do STAT3 inhibitors have potential in the future for cancer therapy? Expert Opin Investig Drugs. 2017;26:853–7.
24. Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC, et al. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res. 2009;69:193–202.
25. Ke F, Wang Z, Song X, Ma Q, Hu Y, Jiang L, et al. Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/AKT/NFκB pathways in cholangiocarcinoma cells. Drug Des Devel Ther. 2017;11:1753–66.
26. Ji Y, Liu Y, Xue N, Du T, Wang L, Huang R, et al. Cryptotanshinone inhibits esophageal squamous-cell carcinoma in vitro and in vivo through the suppression of STAT3 activation. Onco Targets Ther. 2019;12:883–96.
27. Chen Z, Zhu R, Zheng J, Chen C, Huang C, Ma J, et al. Cryptotanshinone inhibits proliferation yet induces apoptosis by suppressing STAT3 signals in renal cell carcinoma. Oncotarget. 2017;8:50023–33.
28. Wang J, Zhang G, Dai C, Gao X, Wu D, Shen L, et al. Cryptotanshinone potentiates the antitumor effects of doxorubicin on gastric cancer cells via inhibition of STAT3 activity. J Int Med Res. 2017;45:220–30.
29. Wang Y, Lu HL, Liu YD, Yang LY, Jiang QF, Zhu XJ, et al. Cryptotanshinone sensitizes antitumor effect of paclitaxel on tongue squamous cell carcinoma by inhibiting BAK/STAT3 signaling pathway. Biomed Pharmacother. 2017;95:1388–96.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.